Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug 9:2:45-52.
doi: 10.2147/ijwh.s9408.

Gender-related mortality for HIV-infected patients on highly active antiretroviral therapy (HAART) in rural Uganda

Arif Alibhai  1 , Walter Kipp, L Duncan Saunders, Ambikaipakan Senthilselvan, Amy Kaler, Stan Houston, Joseph Konde-Lule, Joa Okech-Ojony, Tom Rubaale
Affiliations

Gender-related mortality for HIV-infected patients on highly active antiretroviral therapy (HAART) in rural Uganda

Arif Alibhai et al. Int J Womens Health. .

Abstract

The purpose of this study was to examine gender differences in mortality for human immunodeficiency virus (HIV) patients in rural Western Uganda after six months of highly active antiretroviral therapy (HAART). Three hundred eighty five patients were followed up for six months after initiating HAART. Statistical analysis included descriptive, univariate and multivariate methods, using Kaplan-Meier estimates of survival distribution and Cox proportional hazards regression. Mortality in female patients (9.0%) was lower than mortality in males (13.5%), with the difference being almost statistically significant (adjusted hazard ratio for females 0.55; 95% confidence interval [CI]: 0.28-1.07; P = 0.08). At baseline, female patients had a significantly higher CD4+ cell count than male patients (median 147 cells/μL vs 120 cells/μL; P < 0.01). A higher CD4+ cell count and primary level education were strongly associated with better survival. The higher CD4+ cell count in females may indicate that they accessed HAART services at an earlier stage of their disease progression than males. A borderline statistically significant lower mortality rate in females shows that females fare better on treatment in this context than males. The association between lower mortality and higher CD4+ levels suggest that males are not accessing treatment early enough and that more concerted efforts need to be made by HAART programs to reach male HIV patients.

Keywords: Uganda; antiretroviral treatment; gender; rural.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan–Meier survival curve for males and females (P = 0.16 from log-rank test).
See this image and copyright information in PMC

References

    1. Mathers CD, Sadana R, Salomon JA, Murray CJL, Lopez AD. Healthy life expectancy in 191 countries, 1999. Lancet. 2001;357(9269):1685–1691. - PubMed
    1. US Census Bureau . Global Population Profile: 2002. Washington, DC: US Government Printing Office; 2004.
    1. UNAIDS . AIDS epidemic update: November 2009. Geneva, Switzerland: Joint United Nations Programme on AIDS; 2009.
    1. Baghdadi G. Gender and medicines: An international public health perspective. J Womens Health. 2005;14(1):82–86. - PubMed
    1. Ojikutu BO, Stone VE. Women, inequality, and the burden of HIV. N Engl J Med. 2005;352(7):649–652. - PubMed